

Opportunity Title: CDC Viral Hemorrhagic Fever Therapeutic Research

Fellowship

Opportunity Reference Code: CDC-NCEZID-2022-0125

Organization Centers for Disease Control and Prevention (CDC)

Reference Code CDC-NCEZID-2022-0125

How to Apply *Connect with ORISE...on the GO!* Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation. Your application will be considered incomplete, and will not be reviewed until one recommendation is submitted.

All documents must be in English or include an official English translation.

Application Deadline 9/30/2022 3:00:00 PM Eastern Time Zone

Description *Applications will be reviewed on a rolling-basis.

CDC Office and Location: A research opportunity is currently available in the Viral Special Pathogens Branch (VSBP) within the National Center for Zoonotic and Emerging Infectious Diseases (NCEZID) at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia.

Research Project: The selected participant will be a part of the Molecular Pathogenesis and Therapeutics Team, which is responsible for research on viral diseases including henipaviruses, hantaviruses, filoviruses, bunyaviruses and arenaviruses. Under the guidance of the mentor, the participant will learn and contribute to research on hemorrhagic fever viruses, evaluate therapeutics for such viruses, and collaborate with laboratory and epidemiological staff across CDC.

Learning Objectives: Specific learning research opportunities will focus on the development of candidate therapeutics for agents including henipaviruses, hantaviruses, filoviruses, bunyaviruses and arenaviruses, and may include:

- Learning biosafety level 3 and 4 laboratory practices and regulations
- Learning how to culture and characterize high-hazard viruses
- Learning how to perform therapeutic screening studies under high containment
- Learning how to dissect mechanisms-of-action of candidate antiviral compounds
- The opportunity to participate in national and international meetings, workshops and training courses

Mentor(s): The mentors for this opportunity are Mike Flint (vfa3@cdc.gov) and Christina Spiropoulou (ccs8@cdc.gov). Please contact them if you have questions about the nature of this research.

Anticipated Appointment Start Date: September 2022. Start date is flexible and will depend on a variety of factors.



ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON
 **Google Play**

Download on the
 **App Store**

Opportunity Title: CDC Viral Hemorrhagic Fever Therapeutic Research

Fellowship

Opportunity Reference Code: CDC-NCEZID-2022-0125

Appointment Length: The appointment will initially be for one year, but may be renewed upon recommendation of CDC and is contingent on the availability of funds.

Level of Participation: The appointment is full-time.

Participant Stipend: The participant will receive a monthly stipend commensurate with educational level and experience.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the [Guidelines for Non-U.S. Citizens Details page](#) of the program website for information about the valid immigration statuses that are acceptable for program participation.

ORISE Information: This program, administered by ORAU through its contract with the U.S. Department of Energy (DOE) to manage the Oak Ridge Institute for Science and Education (ORISE), was established through an interagency agreement between DOE and CDC. Participants do not become employees of CDC, DOE or the program administrator, and there are no employment-related benefits. Proof of health insurance is required for participation in this program. Health insurance can be obtained through ORISE.

The successful applicant(s) will be required to comply with Environmental, Safety and Health (ES&H) requirements of the hosting facility, including but not limited to, COVID-19 requirements (e.g. facial covering, physical distancing, testing, vaccination).


Questions: Please visit our [Program Website](#). After reading, if you have additional questions about the application process please email ORISE.CDC.NCEZID@ornl.gov and include the reference code for this opportunity.

Qualifications The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by the end of September 2022. Degree must have been received within five years of the appointment start date.

Preferred skills:

- Experience at biosafety level 2, 3, or 4
- Experience with cell culture, sterile working techniques and methods for viral culturing
- Experience in molecular virological techniques
- Interest in contributing to the discovery of candidate antiviral compounds for hemorrhagic fever viruses

**Eligibility
Requirements**

- **Degree:** Doctoral Degree received within the last 60 months or anticipated to be received by 9/30/2022 11:59:00 PM.
- **Discipline(s):**
 - **Life Health and Medical Sciences** ([6](#) )

Opportunity Title: CDC Viral Hemorrhagic Fever Therapeutic Research
Fellowship

Opportunity Reference Code: CDC-NCEZID-2022-0125